DEVELOPMENT OF PROSTATE-SPECIFIC ANTIGEN PROMOTER-BASED GENE THERAPY FOR ANDROGEN-INDEPENDENT HUMAN PROSTATE CANCER
- 1 July 1998
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Molecular Therapy with Recombinant p53 Adenovirus in an Androgen-Independent, Metastatic Human Prostate Cancer ModelHuman Gene Therapy, 1996
- Expression of bcl-2 From a Defective Herpes Simplex Virus–1 Vector Limits Neuronal Death in Focal Cerebral IschemiaStroke, 1995
- Delayed Morbidity and Mortality of Albumin/SV40 T-Antigen Transgenic Mice after Insertion of an α-Fetoprotein/Herpes Virus Thymidine Kinase Transgene and Treatment with GanciclovirHuman Gene Therapy, 1994
- Antitumoral Effects of Liarozole in Androgen-Dependent and Independent R3327-Dunning Prostate AdenocarcinomasJournal of Urology, 1994
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4.Journal of Clinical Investigation, 1993
- Prostate and Bone Fibroblasts Induce Human Prostate Cancer Growth in Vivo: Implications for Bidirectional Tumor-Stromal Cell Interaction in Prostate Carcinoma Growth and MetastasisJournal of Urology, 1992
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987
- Human prostate-specific antigen: structural and functional similarity with serine proteases.Proceedings of the National Academy of Sciences, 1986
- A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.Journal of Clinical Investigation, 1985